Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ficerafusp alfa + pembrolizumab
- Development stage
- Phase 3
- Lead developer
- Bicara Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ficerafusp alfa + pembrolizumab is an investigational combination therapy under clinical evaluation for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). **Ficerafusp alfa (BCA101)** is a recombinant fusion protein engineered to simultaneously target and inhibit both **Epidermal Growth Factor Receptor (EGFR)** and **Transforming Growth Factor beta (TGF-β)**, two pathways implicated in cancer growth and immune resistance. **Pembrolizumab** is a monoclonal antibody that blocks **programmed cell death protein 1 (PD-1)**, restoring immune response against tumor cells. The combination aims to enhance anti-tumor efficacy through dual pathway inhibition and immune checkpoint blockade. Clinical studies show encouraging antitumor activity, especially in HPV-negative HNSCC, with a manageable safety profile[1][3][5][6].
- Other names
- BCA101 + pembrolizumab
02
Targets
EGFR (Epidermal growth factor receptor)PDCD1 (Programmed cell death protein 1 receptor)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on ficerafusp alfa + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ficerafusp alfa + pembrolizumab.